Advertisement
Singapore markets close in 24 minutes
  • Straits Times Index

    3,234.22
    -17.49 (-0.54%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,950.55
    +18.57 (+0.23%)
     
  • Bitcoin USD

    70,585.05
    +732.66 (+1.05%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • Dow

    39,760.08
    +477.75 (+1.22%)
     
  • Nasdaq

    16,399.52
    +83.82 (+0.51%)
     
  • Gold

    2,215.40
    +2.70 (+0.12%)
     
  • Crude Oil

    81.81
    +0.46 (+0.57%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,256.24
    -53.85 (-0.74%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Why Inovio Shares Rose 61.7% in April

Why Inovio Shares Rose 61.7% in April

Inovio Pharmaceuticals (NASDAQ: INO) shares soared 61.7% in April, according to data provided by S&P Global Market Intelligence, as the company began human trials of its coronavirus vaccine. Inovio started a phase 1 trial of its DNA vaccine for COVID-19, the illness caused by the novel coronavirus, early in April and completed enrollment of 40 healthy adults later in the month. The clinical stage company also said it expanded its agreement with Richter-Helm BioLogics GmbH & Co. of Germany to cover large-scale manufacturing of the vaccine.